Twenty5Twenty

Twenty/Twenty Therapeutics develops innovative solutions for eye diseases by integrating artificial intelligence, microelectronics, and scalable digital technologies. The company focuses on diagnostic, sensing, and preventative, medical, and surgical treatments, aiming to transform traditional eye care delivery. Their technical approach emphasizes the convergence of these advanced systems to create more intuitive and accessible tools for vision health.

The company was established in August 2020 as a strategic joint venture between Verily Life Sciences, an Alphabet company, and Santen, a prominent Japanese pharmaceutical firm. This collaboration was born from the insight that significant innovation was needed to improve patient access to sophisticated eye care and empower individuals in managing their vision.

Twenty/Twenty Therapeutics serves patients and medical professionals, striving to enhance diagnostic capabilities and treatment outcomes. The company's overarching vision is to eliminate preventable blindness globally, achieved through pioneering affordable and intuitive solutions that allow for better care and patient self-management between clinical visits.